论文部分内容阅读
目的:分析探讨胸腺肽治疗重症肺炎的临床疗效以及对白细胞介素-6和白细胞介素-10的影响。方法:将82例患者随机分为观察组与对照组,每组各41例。对照组行抗感染、止咳化痰等常规治疗,观察组在常规治疗的基础上采用肌下胸腺肽注射治疗,观察比较两组患者的疗效、白细胞介素-6(IL-6)和白细胞介素-10(IL-10)的水平变化情况及并发症。结果:观察组的治疗总有效率明显高于对照组(P<0.05)。治疗后观察组患者的IL-6和IL-10含量明显降低,均与对照组相比具有显著性差异(P<0.05)。结论:应用胸腺肽辅助治疗重症肺炎能够明显改善临床症状,纠正炎症细胞因子的平衡,并发症少,值得临床广泛应用推广。
Objective: To investigate the clinical efficacy of thymosin in the treatment of severe pneumonia and its effects on interleukin-6 and interleukin-10. Methods: 82 patients were randomly divided into observation group and control group, 41 cases in each group. The control group received routine treatment such as anti-infection and relieving cough and resolving phlegm. The observation group was given subcutaneous thymosin injection on the basis of routine treatment. The curative effect, interleukin-6 (IL-6) and interleukin -10 (IL-10) levels and complications. Results: The total effective rate of observation group was significantly higher than that of control group (P <0.05). After treatment, the levels of IL-6 and IL-10 in the observation group were significantly lower than those in the control group (P <0.05). Conclusion: The application of thymosin adjuvant treatment of severe pneumonia can significantly improve the clinical symptoms, correct the balance of inflammatory cytokines, fewer complications, it is widely used in clinical promotion.